Theophylline ( DrugBank: Theophylline )


2 diseases
IDDisease name (Link within this page)Number of trials
236Pseudohypoparathyroidism5
299Cystic fibrosis2

236. Pseudohypoparathyroidism


Clinical trials : 6 Drugs : 4 - (DrugBank : 2) / Drug target genes : 20 - Drug target pathways : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04551170
(ClinicalTrials.gov)
July 13, 20209/9/2020Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years OldPhase 2 Study of Theophylline Treatment for PseudohypoparathyroidismPseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1aDrug: Theophylline;Drug: PlaceboVanderbilt University Medical CenterNULLRecruiting2 Years12 YearsAll34Phase 2United States
2NCT04240821
(ClinicalTrials.gov)
May 22, 202021/1/2020Theophylline for Treatment of PseudohypoparathyroidismOpen-Label Extension Study of Theophylline for Treatment of PseudohypoparathyroidismPseudohypoparathyroidism;Pseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: Theophylline ERAshley ShoemakerNULLEnrolling by invitation2 Years99 YearsAll34Phase 2United States
3NCT03718403
(ClinicalTrials.gov)
April 10, 20198/9/2017Effect of Theophylline in PseudohypoparathyroidismEffect of Theophylline in PseudohypoparathyroidismPHP Ia;PHP IB;Php1CDrug: TheophyllineMassachusetts General HospitalNULLNot yet recruiting5 Years21 YearsAll40Phase 4NULL
4NCT03029429
(ClinicalTrials.gov)
September 1, 201818/1/2017Theophylline Treatment for PseudohypoparathyroidismPhase 2 Study of Theophylline Treatment for PseudohypoparathyroidismPseudohypoparathyroidism;Albright Hereditary OsteodystrophyDrug: Theophylline;Drug: PlacebosVanderbilt University Medical CenterHarvard UniversityRecruiting13 Years99 YearsAll34Phase 2United States
5NCT02463409
(ClinicalTrials.gov)
June 201520/5/2015Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1aPseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: TheophyllineVanderbilt University Medical CenterMassachusetts General HospitalCompleted10 Years21 YearsAll6Phase 2United States

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01684683
(ClinicalTrials.gov)
November 201211/9/2012The Effect of Theophylline in the Treatment of BronchiectasisClinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) BronchiectasisBronchiectasisDrug: Theophylline;Drug: Placebo(for Theophylline)The First Affiliated Hospital of Guangzhou Medical UniversityNULLCompleted18 Years70 YearsBoth100Phase 4China
2ChiCTR-TRC-12002470
2012-09-152012-08-02The effect of theophylline in the treatment of bronchiectasis, a random, double blind studyThe effect of theophylline in the treatment of bronchiectasis, a random, double blind study. bronchiectasis not due to cystic fibrosis1:theophylline;2:theophylline;The first affiliated hospital of Guangzhou Medical UniversityNULLCompleted1565Both1:46;2:46;China